[Federal Register Volume 67, Number 221 (Friday, November 15, 2002)]
[Notices]
[Page 69226]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-28940]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on December 17, 2002, from 
8:30 a.m. to 5 p.m.
    Location: Bethesda Marriott Hotel, 5151 Pooks Hill Rd., Bethesda, 
MD.
    Contact Person: Jody G. Sachs or Denise H. Royster, Center for 
Biologics Evaluation and Research (HFM-71), Food and Drug 
Administration, 301-827-0314, or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 
12391. Please call the Information Line for up-to-date information on 
this meeting.
    Agenda: The committee will review and discuss safety and efficacy 
and proposed indications for the product, FluMist, a cold-adapted, live 
attenuated, trivalent influenza vaccine for the prevention of influenza 
sponsored by MedImmune Vaccines, Inc.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by December 1, 
2002. Oral presentations from the public will be scheduled between 
approximately 1 p.m. and 2 p.m. Time allotted for each presentation may 
be limited. Those desiring to make formal oral presentations should 
notify the contact person before December 1, 2002, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Jody G. Sachs or 
Denise H. Royster at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: November 7, 2002.
Linda Arey Skladany,
Senior Associate Commissioner for External Relations.
[FR Doc. 02-28940 Filed 11-14-02; 8:45 am]
BILLING CODE 4160-01-S